vimarsana.com

Page 7 - டர்கு பல்கலைக்கழகம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novel PET tracer is safe and can clearly identify early stages of rheumatoid arthritis

Novel PET tracer is safe and can clearly identify early stages of rheumatoid arthritis New research shows that a novel positron emission tomography (PET) tracer that targets inflammation is safe and can clearly identify early stages of rheumatoid arthritis. The promising PET tracer, 68Ga-DOTA-Siglec-9, rapidly clears from blood circulation, has a low radiation dose, and can be easily produced. This first-in-human study was published in the April issue of the Journal of Nuclear Medicine. Inflammation is a significant part of several chronic diseases, including rheumatoid arthritis and its related issues. While PET imaging with 18F-FDG is a valuable tool for the diagnosis and monitoring of the effects of treatments, it is not specific enough to assess inflammation.

Novel PET radiopharmaceutical shows promising results in first-in-humans study

Novel PET radiopharmaceutical shows promising results in first-in-humans study The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well tolerated and safe. The radiopharmaceutical is 68Ga-labelled Siglec-9 peptide. The dose of the radiopharmaceutical used in PET imaging is thousands of times lower when compared with the regular drugs. Studies with new radiopharmaceuticals are therefore safer than the usual drug research studies.

Promising results from first-in-humans study of a novel PET radiopharmaceutical

 E-Mail IMAGE: The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. view more  Credit: Anne Roivainen The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well tolerated and safe. The radiopharmaceutical is 68Ga-labelled Siglec-9 peptide.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.